Read by QxMD icon Read

bevacizumab with folfox in metastatic colon cancer

Yasar Subutay Peker, Mehmet Fatih Can, Ismail Hakki Ozerhan, Gokhan Yagci, Nazif Zeybek, Kutan Kavakli, Sedat Gurkok, Alper Gozubuyuk, Onur Genc, Gokhan Erdem, Ahmet Ozet, Mustafa Gerek, Yusuf Peker
The main method of fighting against colon cancer is targeted treatment. BRAF inhibitors, which are accepted as standard treatment for V600E mutant malign melanomas, are the newest approach for targeted treatment of V600E mutant colorectal cancers. In this case report, we share our experience about the use of BRAF inhibitor vemurafenib on a V600E mutant metastatic right colon adenocarcinoma patient. A 59-year-old male with only lung multiple metastatic V600E mutant right colon cancer presented to our clinic...
2018: Case Reports in Surgery
Seung Tae Kim, Hee Kyung Kim, Jeeyun Lee, Se Hoon Park, Ho Yeong Lim, Young Suk Park, Won Ki Kang, Joon Oh Park
Purpose: We aimed to evaluate the effect of bevacizumab in metastatic CRC (colorectal cancer) regarding to microsatellite instability (MSI) and the sidedness of the primary tumor. Materials and Methods: A total of 140 CRC patients were retrospectively analyzed, who received bevacizumab-containing chemotherapy between April 2008 and January 2013. MSI status and Kirsten RSAS (KRAS) mutational status were available in all 140 patients, but BRAF (the gene for the B-type Raf kinase) mutational status was only available in 74 patients (52...
2018: Journal of Cancer
Satya Das, Kristen K Ciombor, Sigurdis Haraldsdottir, Richard M Goldberg
Choosing the optimal treatment approach for patients with metastatic colorectal cancer (mCRC) demands that oncologists assess both clinical and genomic variables and individualize care based upon the findings. Clinically, choices depend on assessing the side of the colon in which the primary tumor originates, the sites and burden of metastatic disease, the patient's performance status, and their individual comorbidities. Genomic assessment of the tumor to discern the mutational status of genes such as RAS/RAF, HER2, and TRK, as well as assessing whether tumors have defective mismatch repair (dMMR) or high microsatellite instability (MSI-H), all factor in to potential treatment options and can determine clinical trial eligibility...
May 11, 2018: Current Treatment Options in Oncology
Masaaki Akai, Shinya Otsuka, Yuichi Yasui, Kenta Isoda, Ryousuke Hamano, Naoyuki Tokunaga, Kenji Takahashi, Hideaki Miyaso, Yousuke Tsunemitsu, Kazuhide Iwakawa, Masaru Inagaki, Hiromi Iwagaki
The patient was a man in his early 30s. He underwent sigmoidectomy with D3+ #216 for advanced sigmoid colon cancer with metastatic para-aortic lymph nodes. The pathological diagnosis was colon cancer(S), type 2, moderately differentiated, pT4a(SE), pN3(19/33), pM1a(LYM), pStage IV , KRAS wild-type, EGFR(+). He received FOLFOX plus bevacizumab(Bmab) as adjuvant chemotherapy. One year postoperatively, he experienced recurrence as multiple lung metastases. FOLFIRI plus panitumumab, SOX plus Bmab, CapeOX, nivolumab and FOLFIRI plus ramucirumab were then administered...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Edita Baltruskeviciene, Diana Schveigert, Vaidotas Stankevicius, Ugnius Mickys, Tadas Zvirblis, Jaroslav Bublevic, Kestutis Suziedelis, Eduardas Aleknavicius
BACKGROUND: MiRNAs are often deregulated in colorectal cancer and might function as tumor suppressors or as oncogenes. They participate in controlling key signaling pathways involved in proliferation, invasion and apoptosis and may serve as prognostic and predictive markers. In this study we aimed to evaluate the role of miRNA-148a and miRNA-625-3p in metastatic colorectal cancer. METHODS: Fifty-four patients with a first-time diagnosed CRC receiving FOLFOX ± Bevacizumab were involved in the study...
September 1, 2017: BMC Cancer
N Boeckx, R Koukakis, K Op de Beeck, C Rolfo, G Van Camp, S Siena, J Tabernero, J-Y Douillard, T André, M Peeters
Background: Previous studies have reported the prognostic impact of primary tumor sidedness in metastatic colorectal cancer (mCRC) and its influence on cetuximab efficacy. The present retrospective analysis of two panitumumab trials investigated a possible association between tumor sidedness and treatment efficacy in first-line mCRC patients with RAS wild-type (WT) primary tumors. Materials and methods: Data from two randomized first-line panitumumab trials were analyzed for treatment outcomes by primary tumor sidedness for RAS WT patients...
August 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
M Del Rio, C Mollevi, F Bibeau, N Vie, J Selves, J-F Emile, P Roger, C Gongora, J Robert, N Tubiana-Mathieu, M Ychou, P Martineau
BACKGROUND: Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab. The aim of this study was to evaluate if recently identified molecular subtypes of colon cancer are associated with response of metastatic patients to first-line therapy. PATIENTS AND METHODS: We collected and analysed 143 samples of human colorectal tumours with complete clinical annotations, including the response to treatment...
May 2017: European Journal of Cancer
Jeffrey Chen, Roger D Smalligan, Suhasini Nadesan
INTRODUCTION: Colorectal cancer is the third most common cancer in the United States. The use of bevacizumab (Avastin), a vascular endothelial growth factor (VEGF) inhibitor, has been increasing due to observed improvement in metastatic colon cancer survival, but so has the incidence of bowel perforation. We present one unusual complication of bowel perforation, a colovesical fistula in a colorectal cancer patient treated with bevacizumab. CASE PRESENTATION: A 54-year-old white male diagnosed with Stage IV colorectal cancer was treated with folinic acid, leucovorin, fluorouracil, oxaliplatin (FOLFOX) and bevacizumab...
August 2016: Hospital Practice (Minneapolis)
Brian S Seal, Sibyl Anderson, Kenneth M Shermock
BACKGROUND: Over the past decade, oncology therapies have trended toward orally administered regimens, and there has been growing attention on evaluation of factors that affect adherence. There has not been a rigorous investigation of factors associated with adherence to intravenous (i.v.) and oral anticancer drugs in the setting of metastatic colorectal cancer (mCRC). OBJECTIVES: To (a) assess potential patient-specific factors related to adherence to mCRC chemotherapy regimens and (b) compare adherence with IV versus oral dosage forms...
March 2016: Journal of Managed Care & Specialty Pharmacy
Nguyen H Tran, Ludmila L Cavalcante, Sam J Lubner, Daniel L Mulkerin, Noelle K LoConte, Linda Clipson, Kristina A Matkowskyj, Dustin A Deming
When considering treatment options for patients with metastatic colorectal cancer (mCRC), molecular profiling has become a pivotal component in guiding clinical decisions. FOLFOX and FOLFIRI (fluorouracuil, leucovorin plus oxaliplatin or ininotecan, respectively) are the standard base regimens used for the treatment of mCRC. Biologic agents, such as the epidermal growth factor receptor (EGFR) targeted therapies, cetuximab and panitumumab and the vascular endothelial growth factor monoclonal antibody, bevacizumab, are safe and effective in the first-line setting...
September 2015: Therapeutic Advances in Medical Oncology
Alessandro Passardi, Emanuela Scarpi, Stefano Tamberi, Luigi Cavanna, Davide Tassinari, Annalisa Fontana, Sara Pini, Ilaria Bernardini, Caterina Accettura, Paola Ulivi, Giovanni Luca Frassineti, Dino Amadori
BACKGROUND: To investigate the impact of pre-treatment lactate dehydrogenase (LDH) levels on the outcome of patients with metastatic colorectal cancer treated with first-line chemotherapy with or without the anti-VEGF monoclonal antibody, bevacizumab, in a phase III prospective multicentre randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial. METHODS: Three hundred and seventy patients enrolled onto the ITACa first-line trial were considered for this study, 176 receiving chemotherapy (either FOLFIRI or FOLFOX) plus bevacizumab and 194 receiving chemotherapy only...
2015: PloS One
Tomonori Morimoto, Yoshihiro Yata, Yoshikuni Yonenaga, Kouji Hanaki, Masahiro Mise, Shunichi Higaside, Yuuji Kanda, Hideki Noda
Chemotherapy with S-1 and oxaliplatin is a new treatment for metastatic colorectal cancer. We present the first case of S-1, oxaliplatin, and bevacizumab therapy in our hospital. The patient was a 69-year-old woman with ascending colon cancer and multiple lung and liver metastases. She tended to suffer from constipation; stenoses at the cecum and colon cancer were detected by colon fiberscopy. Following surgical resection of the primary tumor, the patient received systemic chemotherapy with S-1, oxaliplatin, and bevacizumab...
June 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Soichi Tsutsumi, Takaaki Fujii, Satoru Yamaguchi, Toshinaga Suto, Reina Yajima, Hiroki Morita, Toshihide Kato, Takayuki Asao, Hiroyuki Kuwano
BACKGROUND/AIMS: We evaluated the efficacy and safety of bevacizumab for metastatic colorectal cancer patients. METHODOLOGY: All unresectable metastatic colorectal cancer patients who began receiving bevacizumab at participating facilities from 2006 to 2011 were retrospectively analyze to determine the safety and efficacy. The primary end points were Progression Free Survival (PFS) and Overall Survival (OS). The secondary end points were adverse events. RESULTS: A total of 101 patients were enrolled in the study...
May 2014: Hepato-gastroenterology
Hong Shen, Jiao Yang, Qing Huang, Meng-Jie Jiang, Yi-Nuo Tan, Jian-Fei Fu, Li-Zhen Zhu, Xue-Feng Fang, Ying Yuan
The colon is derived from the embryological midgut and hindgut separately, with the right colon and left colon having different features with regards to both anatomical and physiological characteristics. Cancers located in the right and left colon are referred to as right colon cancer (RCC) and left colon cancer (LCC), respectively, based on their apparent anatomical positions. Increasing evidence supports the notion that not only are there differences in treatment strategies when dealing with RCC and LCC, but molecular features also vary between them, not to mention the distinguishing clinical manifestations...
June 7, 2015: World Journal of Gastroenterology: WJG
Concetta Martines, Stefano Cordio, Roberto Bordonaro
We report a case of a young adult affected by an adenocarcinoma of the ascending colon with synchronous, unresectable liver metastases, diagnosed on April, 2011. The patient received a first-line of bio-chemotherapy with standard folfox regimen in association with bevacizumab. Deriving from which a good partial remission of the disease with its conversion to operability; so he underwent a right hemicolectomy with liver metastasectomy. Eleven months after radical surgery, the patient experimented an intrahepatic progression of the tumour, so he started a second-line therapy with FOLFIRI regimen plus aflibercept...
May 2015: Recenti Progressi in Medicina
Jerome C Landry, Yang Feng, Roshan S Prabhu, Steven J Cohen, Charles A Staley, Richard Whittington, Elin Ruth Sigurdson, Halla Nimeiri, Udit Verma, Al Bowen Benson
LESSONS LEARNED: The 5-year oncologic outcomes from the trial regimen were excellent. However, the neoadjuvant and surgical toxicity of this regimen was significant and was the primary reason for the low compliance with adjuvant systemic therapy.Due to the lack of an improvement in the pathologic complete response rate, the substantial associated toxicity, and the negative phase III trials of adjuvant bevacizumab in colon cancer, this regimen will not be pursued for further study. BACKGROUND: The addition of bevacizumab to chemotherapy improves overall survival for metastatic colorectal cancer...
June 2015: Oncologist
Mutsumi Fukunaga, Ken Nakata, Akihito Babaya, Katsushu Shimizu, Takahiko Ishigaki, Takeshi Ebihara, Satoshi Okubo, Fumitaka Kato, Kouji Amano, Hiromitsu Hoshino, Ryohei Kawabata, Jun Yamamura, Shunji Kamigaki, Akihiro Usui, Naoki Ikeda, Tameyoshi Yamamoto, Tomono Kawase, Yutaka Kimura, Hiroki Ohzato
A 58-year-old woman was confirmed as having multiple liver metastases after undergoing a high anterior resection for a sigmoid colon tumor. She was administered bevacizumab+FOLFOX as the first regimen and bevacizumab+FOLFIRI and S-1 and irinotecan (IRIS)therapy as the second regimen. During this treatment she also underwent hepatectomy 3 times and radiofrequency ablation once. She was administered panitumumab+irinotecan as the third regimen and, due to the presence of multiple pulmonary metastases, was subsequently considered to have had a partial response (PR)...
November 2014: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Kentaro Gokita, Katsunori Ami, Yutaro Matsunaga, Keiichi Fujiya, Nana Ohshima, Hidetoshi Amagasa, Hideaki Ganno, Kenichiro Imai, Akira Fukuda, Takeshi Nagahama, Masayuki Ando, Hidetaka Akita, Shikofumi Tei, Youichi Okada, Kuniyoshi Arai
A case of successful chemotherapy for a metachronous liver metastasis following resection for sigmoid colon cancer is presented. A 51-year-old man underwent sigmoidectomy, ileocecal resection, and descending colon colostomy for sigmoid colon cancer with ileum invasion. Six courses of FOLFOX4 were performed as adjuvant chemotherapy. One year after sigmoidectomy, a liver metastasis was detected on computed tomography (CT) examination. Chemotherapy with FOLFOX+bevacizumab was restarted. Three courses were administered, but hepatic dysfunction occurred after the second and third courses, and FOLFOX was discontinued...
November 2014: Gan to Kagaku Ryoho. Cancer & Chemotherapy
Satoshi Teramae, Hiroshi Miyamoto, Naoki Muguruma, Yasuyuki Okada, Takahiro Goji, Shinji Kitamura, Tetsuo Kimura, Masako Kimura, Yoshimi Bando, Tetsuji Takayama
A 45-year-old man was referred to our hospital and found to have a tubular adenocarcinoma of the descending colon with multiple liver metastases. During hospitalization, the patient suffered recurrent hypoglycemic attacks that required intravenous 50% glucose infusion. He was diagnosed with non-islet cell tumor hypoglycemia (NICTH) because the colon cancer tissue obtained by biopsy was strongly stained for insulin-like growth factor-II (IGF-II) by immunohistochemistry. He received chemotherapy with oxaliplatin, 5-FU and leucovorin (FOLFOX) plus bevacizumab (Bmab), and showed a partial response...
February 2015: Clinical Journal of Gastroenterology
Anne Marie C Flaherty
A 65-year-old Polish immigrant named T. J. was diagnosed with metastatic colon cancer in January 2012 when he presented with obstructing sigmoid colon cancer and liver metastases. A diverting colostomy as well as biopsy of his liver metastases was performed and chemotherapy with FOLFOX (5-fluorouracil [5-FU], leucovorin, oxaliplatin) and bevacizumab was initiated. After three months, he transitioned to maintenance therapy with infusional 5-FU and bevacizumab until he progressed in August 2012. Oxaliplatin was reintroduced and he responded until he developed progressive neuropathy in November and his therapy was changed to FOLFIRI (5-FU, leucovorin, irinotecan) and bevacizumab...
January 2015: Oncology Nursing Forum
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"